248 related articles for article (PubMed ID: 11908555)
1. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
2. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
[TBL] [Abstract][Full Text] [Related]
3. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
4. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
7. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
9. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
Yocum DE; Furst DE; Kaine JL; Baldassare AR; Stevenson JT; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisemandle W; Mekki QA;
Arthritis Rheum; 2003 Dec; 48(12):3328-37. PubMed ID: 14673984
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.
Barnett ML; Kremer JM; St Clair EW; Clegg DO; Furst D; Weisman M; Fletcher MJ; Chasan-Taber S; Finger E; Morales A; Le CH; Trentham DE
Arthritis Rheum; 1998 Feb; 41(2):290-7. PubMed ID: 9485087
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
[TBL] [Abstract][Full Text] [Related]
15. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.
Yocum DE; Furst DE; Bensen WG; Burch FX; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisememandle W; Mekki QA;
Rheumatology (Oxford); 2004 Aug; 43(8):992-9. PubMed ID: 15014199
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
Kondo H; Abe T; Hashimoto H; Uchida S; Irimajiri S; Hara M; Sugawara S
J Rheumatol; 2004 Feb; 31(2):243-51. PubMed ID: 14760792
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
